In an follow-up on the previous report on a multi-state outbreak of Burkholderia cepacia infections possibly linked to liquid docusate products, the Centers for Disease Control and Prevention (CDC) issued the following update Wednesday:
Preliminary information continues to indicate that contaminated oral liquid docusate products might be related to infections in one state. At this time, there is no epidemiologic or laboratory evidence to suggest oral capsules or enemas are affected. Until more information is available, CDC continues to recommend that facilities not use any oral liquid docusate products for patients who are critically ill, ventilated, or immunosuppressed. Facilities experiencing clusters of B. cepacia infections should sequester all oral liquid docusate products.
Healthcare providers and laboratories should remain on alert for B. cepacia cases occurring among non-cystic fibrosis patients and should inform infection prevention staff when these infections occur. In addition, clusters of B. cepacia infections among patients with CF can be reported when infection rates appear above endemic rates. Cases should be reported to state or local public health authorities.
Related:
- Burkholderia cepacia outbreak at Australian hospital linked to contaminated mouthwash
- U.S. Virgin Islands reports additional Zika and dengue cases
- FDA clears Xpert Carba-R Assay, detects genetic markers linked to Carbapenem resistance
